Feedback / Questions
vobramitamab duocarmazine (MGC018) - MacroGenics
Vobra Duo: Data from P2/3 Tamarack trial (NCT05551117) for castration-resistant prostate cancer in 2024
(Macrogenics)
-
May 11, 2023 -
Corporate Presentation
P2/3 data
•
Oncology • Prostate Cancer
http://ir.macrogenics.com/static-files/4188cbdd-3956-4297-aaaa-fc769b4074e2
May 11, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious